Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728806 | 0.80 | MRGPRX4 (0.60) | PTGDR2TDP1MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL30680095 | 0.77 | RXRA (0.59) | PTGDR2TDP1MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL1577431 | 0.77 | RXRA (0.59) | PTGDR2TDP1MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL7214267 | 0.76 | ALOX5 (0.36) | PTGDR2ALOX5ALOX5APMRGPRX4GCGR | |
| SCHEMBL12147549 | 0.73 | PTGDR2 (0.65) | PTGDR2TDP1MAPTFFAR1 | |
| SCHEMBL14919700 | 0.72 | PTGDR2 (0.53) | PTGDR2TDP1FFAR1 | |
| Propene SCHEMBL9811670 | 0.71 | L3MBTL1 (0.50) | PTGDR2TDP1MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL1690239 | 0.71 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL17896573 | 0.71 | PTGDR2 (0.51) | PTGDR2TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL5131387 | 0.71 | FABP4 (0.45) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481597-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2013-07-09 | — | — | US | claimed |
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-1614418-B1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX INC (US) | 2011-09-14 | — | — | EP | claimed |
| US-7576131-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2009-08-18 | — | — | US | claimed |
| EP-1614418-A1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX, INC. (US) | 2006-01-11 | — | — | EP | claimed |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. | 2003-11-27 | — | — | US | claimed |
| US-10137112-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2775836-B1 | METHODS FOR TREATING GOUT FLARES | CYMABAY THERAPEUTICS INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180214420-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180055803-A1 | Methods for Treating Gout Flares | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9801860-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160271111-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9439891-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | CYMABAY THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-2773336-A1 | METHODS FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND A SECOND URATE-LOWERING AGENT | METABOLEX, INC. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130302305-A1 | Methods for Treating Gout in Patients Subpopulations | METABOLEX, INC. | 2013-11-14 | — | — | US | disclosed |
| WO-2013155478-A1 | METHOD FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND AN ANTI-INFLAMMATORY AGENT | METABOLEX, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274331-A1 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent | DIATEX, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130172368-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent | METABOLEX, INC. | 2013-07-04 | — | — | US | disclosed |
| WO-2013066353-A1 | METHODS FOR TREATING GOUT FLARES | METABOLEX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013066349-A1 | METHODS FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND A SECOND URATE-LOWERING AGENT | METABOLEX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10137112-B2 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PTGDR2 4668/4885ALOX5 1348/4885ALOX5AP 2189/4885 |
| US-20130274331-A1 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent | NUDT1, LIPA, HACL2 | PTGDR2 4040/4885ALOX5 606/4885ALOX5AP 1787/4885 |
| US-20180055803-A1 | Methods for Treating Gout Flares | SLC10A1, LIPA, NUDT1 | PTGDR2 3455/4885ALOX5 246/4885ALOX5AP 920/4885 |
| US-20180214420-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PTGDR2 4668/4885ALOX5 1348/4885ALOX5AP 2189/4885 |
| US-20130302305-A1 | Methods for Treating Gout in Patients Subpopulations | OAT, SLC10A1, XDH | PTGDR2 2850/4885ALOX5 484/4885ALOX5AP 1290/4885 |
| US-20130172368-A1 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent | PON1, XDH, LIPA | PTGDR2 4666/4885ALOX5 1463/4885ALOX5AP 2557/4885 |
| US-20160271111-A1 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | NUDT1, HACL2, XDH | PTGDR2 4668/4885ALOX5 1348/4885ALOX5AP 2189/4885 |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | HACL2, SLC5A2, HCAR2 | PTGDR2 3382/4885ALOX5 571/4885ALOX5AP 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.